| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T651 |
0-436 |
Sentence |
denotes |
The efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: |
| T652 |
437-470 |
Sentence |
denotes |
40 mg, q12h, for 5 days. placebo: |
| T653 |
471-496 |
Sentence |
denotes |
100 mg/d, qn, for 14 days |
| T654 |
497-733 |
Sentence |
denotes |
Experimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: |
| T655 |
734-771 |
Sentence |
denotes |
40 mg, q12h, for 5 days. thalidomide: |
| T656 |
772-854 |
Sentence |
denotes |
100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement |
| T657 |
855-1602 |
Sentence |
denotes |
Secondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020 |
